These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: Evaluation of IBMX-enhanced ocular hypotension after adrenergic agonists in the rabbit eye. Author: Busch MJ, Hoyng PF. Journal: Graefes Arch Clin Exp Ophthalmol; 1995 May; 233(5):296-301. PubMed ID: 7542619. Abstract: BACKGROUND: 3-Isobutyl-1-methylxanthine (IBMX), a phosphodiesterase inhibitor, enhanced the reduction of intraocular pressure more after administration of norepinephrine and epinephrine than after isoproterenol. The question arises of whether or not the IBMX-induced enhancement of ocular hypotension is exclusively due to beta 2-adrenoceptor/cAMP stimulation. METHODS: In groups of eight rabbits the ocular hypotensive responses after selective adrenergic agonists were studied in the presence and absence of phosphodiesterase inhibition with IB-MX. RESULTS: Pretreatment with IBMX 1%, applied topically, did not enhance the ocular hypotensive responses after phenylephrine (alpha 1), B-HT920 (alpha 2) and dobutamine (beta 1). The ocular hypotensive responses induced by salbutamol (0.001-0.5%) and higher concentrations of terbutaline were significantly enhanced by IBMX. Combined treatments of terbutaline 0.01% and B-HT920 0.2%, dobutamine 3% and phenylephrine 2%, and dobutamine 3% and B-HT920 0.2% were not associated with enhanced ocular hypotensive responses in the presence of IBMX. The only combination that was associated with a significant enhancement of ocular hypotension when combined with 1% IBMX was phenylephrine 2% and terbutaline 0.01%. A subthreshold dose of phenylephrine 0.1% further increased the enhanced ocular hypotensive responses induced by salbutamol 0.025, 0.2 and 0.5% in combination with IBMX. CONCLUSIONS: Phosphodiesterase inhibition with IB-MX enhances the ocular hypotensive effect induced by catecholamines not only by beta 2-adrenoceptor/cAMP stimulation, but also by simultaneous alpha 1-adrenoceptor stimulation.[Abstract] [Full Text] [Related] [New Search]